Tranexamic acid did not increase complications in patients with intertrochanteric fracture
Click Here to Manage Email Alerts
Results showed tranexamic acid administration was not associated with increased mortality, deep venous thrombosis, pulmonary embolism, myocardial infarction or stroke in high-risk patients with intertrochanteric hip fractures.
To evaluate the safety and efficacy of tranexamic acid (TXA) for patients with surgically treated intertrochanteric hip fractures, Steven B. Porter, MD, and investigators at the Mayo Clinic in Jacksonville, Florida analyzed 1,147 patients who underwent surgery for these fractures between 2015 and 2019. Among the cohort, 800 patients had surgery performed without TXA and 347 patients had surgery performed with TXA.
Researchers compared propensity scores between high- and low-risk patients and those who received TXA vs. those without TXA. Other outcome measures included postoperative mortality, deep venous thrombosis, pulmonary embolism, myocardial infarction and stroke within 90 days of surgery, according to the study.
Overall, Porter and colleagues found no association between TXA administration and increased risk of any complication or mortality between the groups. Researchers specifically noted no differences in complications or mortality between a matched cohort of 282 high-risk patients with and those without TXA.
“In this propensity-matched study of high-risk patients receiving TXA during surgical repair of [intertrochanteric] IT fractures, we found no evidence of increased mortality risk or other serious adverse outcomes,” the researchers wrote in the study. “These results held for both the high-risk and entire-population cohorts,” they wrote.
Collapse
Read more about
Click Here to Manage Email Alerts